10578 Science Center Drive
Suite 125
San Diego, CA 92121
United States
858 401 7900
https://www.aviditybiosciences.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 253
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Troy Edward Wilson J.D., Ph.D. | Co-Founder & Chairman | 67.5k | N/A | 1969 |
Ms. Sarah Boyce | President, CEO & Director | 1.05M | 1.08M | 1972 |
Mr. Michael F. MacLean | Chief Financial & Chief Business Officer | 701.64k | N/A | 1966 |
Dr. W. Michael Flanagan Ph.D. | Chief Scientific & Technical Officer | 678.74k | N/A | 1962 |
Ms. Teresa McCarthy | Chief Human Resources Officer | 665.14k | N/A | 1964 |
Mr. Eric B. Mosbrooker | Chief Strategy Officer | 42.5k | N/A | 1968 |
Prof. Mark E. Davis | Scientific Founder, Member of Scientific Advisory Board and Member of Board of Managers | N/A | N/A | N/A |
Dr. Frank P. McCormick Ph.D. | Scientific Founder & Member of Scientific Advisory Board | N/A | N/A | 1950 |
Mr. Geoffrey M. Grande C.F.A. | VP of Investor Relation & Corporate Communication | N/A | N/A | N/A |
Dr. John W. Wallen III | VP of Intellectual Property, General Counsel & Secretary | N/A | N/A | 1958 |
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Avidity Biosciences, Inc.’s ISS governance QualityScore as of 1 April 2024 is 9. The pillar scores are Audit: 8; Board: 9; Shareholder rights: 8; Compensation: 8.